Skip to main content
CUE logo

Cue Biopharma, Inc. (CUE) Stock: Price, Forecast & Analyst Target

Cue Biopharma, Inc. (CUE) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $4.50 (-5.46%), as of the Nov 19, 2026 trading session; market cap $37.6M.

Educational signal · not a buy or sell recommendation · How to read this

$4.50 −$0.26 (-5.46%) Market Cap $37.6M

Cue Biopharma, Inc. · CUE · NASDAQ

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic drugs for immunomodulation.

Price as of Nov 19, 2026

Key Statistics

34 of 100

MoonshotScore v2 · Cue Biopharma (CUE)

Weak
Business Quality Poor (18)
Financial Safety Fragile (17)
Valuation Full (50)
Growth Durability Fading (39)
Momentum Falling (13)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet, weak growth and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Poor; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Falling.

  • quarterly revenue $8M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 5 of the last 8 reports

Holding back: weak fundamentals, balance-sheet strain, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CUE (57 recorded, newest six shown)
RecordedScoreBand
17Weak
17Weak
17Weak
17Weak
34Weak
34Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.50
Change on the day-5.46%
Market capitalisation$37.6M—
Shares traded on the day2.06M

Price & events

Other perspectives

Council score for Cue Biopharma (CUE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Negative

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Cue Biopharma (CUE), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cue Biopharma, Inc. (CUE) is listed on NASDAQ. It employs 29 people. In Q2 FY2026 it reported revenue of $8M and net income of -$153M. The market values it at $37.6M.

2 · Latest results

What do the latest results show for Cue Biopharma (CUE)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $8M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$8M-$153M-$24.14 (diluted)
Q1 FY2026$6M-$5M-$1.08 (diluted)
Q4 FY2025$22M$2M$0.43 (diluted)
Q3 FY2025$2M-$7M-$2.21 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Cue Biopharma (CUE)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Piotroski F 2. Trailing ratios: current ratio 3.38.

4 · What to check next?

What should you watch next at Cue Biopharma (CUE)?

Short answer · as of

Current published price targets run low $83.00 · high $83.00 · consensus $83.00 · median $83.00 against a quoted price of $4.50 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Cue Biopharma compare with its peers?

Short answer

Cue Biopharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Cue Biopharma (CUE) — this page$4.50$37.6M34

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$83.00 – $83.00
Consensus target
$83.00
Median target
$83.00

Consensus record · Captured .

Measured against a quoted price of $4.50 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CUE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CUE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Cue Biopharma Stock: Key Questions Answered

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for CUE?

CUE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CUE a good stock to buy?

Stock Expert AI does not rate CUE buy, sell or hold. Cue Biopharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CUE stock price today?

The last price recorded for Cue Biopharma, Inc. (CUE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CUE price target?

The analyst consensus price target for Cue Biopharma, Inc. (CUE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for CUE?

Cue Biopharma, Inc. (CUE) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic partnerships can also provide access to new technologies and markets. Not financial advice.

How frequently does CUE data refresh on this page?

CUE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CUE's recent stock price performance?

Cue Biopharma, Inc. (CUE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Immuno-STAT technology platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CUE overvalued or undervalued right now?

Cue Biopharma, Inc. (CUE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of CUE?

Fractional-share availability for Cue Biopharma, Inc. (CUE) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 12 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.